Murky Response Measures Shouldn’t Block Accelerated Approval Of GSK’s Arzerra, ODAC Says

Meeting at the ASCO annual meeting, the panel votes 10-3 that an ORR of 42 percent is likely to predict clinical benefit in chronic lymphocytic leukemia patients refractory to two drugs.